  
|
 |
| December 2007 |
Article |
|
Boost for research into photodynamic cancer therapiesBoost for research into photodynamic cancer therapies
In photodynamic therapy, a photosensitive drug is administered to a cancer patient. The photo-sensitiser gathers in the cancerous tissue and when the photo-sensitiser is irradiated with light of a specific wavelength, it generates toxic radicals that kill the surrounding cancerous tissue. Research in this field has just received a major boost by the joining of forces of Rhodes University, with its established track record of developing photosensitive drugs for photodynamic therapy, and the CSIR, with its growing skills and facilities for preclinical testing of novel medical laser applications. The two organisations signed a memorandum of understanding outlining the scope and conditions of their research collaboration over the next two years. Professor Tebello Nyokong, DST/NRF Professor of Medicinal Chemistry and Nanotechnology at Rhodes's Department of Chemistry, has been working tirelessly to take her research into light-sensitive drugs to the next phase - and ultimately to introduce advanced cancer-fighting drugs. Nyokong comments, "Our research team at the Department of Chemistry is rearing to start preclinical testing, in collaboration with the CSIR, of molecules that we hope will on the one hand validate our belief that we have developed something immensely promising, and on the other hand give us the opportunity to further refine and develop a treatment that could hold the key to relief for countless cancer patients. We are excited about this development and pleased to be working with the CSIR National Laser Centre," she says. Dr Jan Dam, biophotonics research group leader at the CSIR, says this formal collaboration agreement is just what is needed to progress promising research from laboratory phase to preclinical tests. "One of the benefits we bring to the table is a facility where synthetic, 3D tissue models - based on human cell samples - are manufactured. These artificial, but living tissue models, resemble real human tissue very well and various lesions, for example cancer, can be induced into the tissue models. It is a convenient, cost-effective and risk-free environment for preclinical testing where novel medical laser applications can be truly optimised," says Dam. Another example of what scientists can achieve in the new facility is mathematical modelling and computer simulations of how light spreads in human tissue. "We can also determine the absorption and scattering properties of human tissue and body fluids," explains Dam. "We are hugely encouraged by this development. The field of biomedical optics is highly multidisciplinary. To succeed - and to get to research breakthroughs - collaboration is key. We are optimistic that this agreement will pave the way for a breakthrough that could ultimately see a highly effective, South African-developed treatment for those affected by cancer," he says. - CSIR E-news. More information:
Rhodes University - www.ru.ac.za Related articles:
|
|||||||||||||||||||
Science in Africa - Africa's First On-Line Science Magazine |
||||||||||||||||||||
    |
||||||||||||||||||||
Copyright Science in Africa, Science magazine for Africa CC. All Rights Reserved
|
||||||||||||||||||||
CSIR